secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000950170-23-060244
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector Q3 net loss $44.5M ($0.53/share); cash runway through 2025
------------------------------------------------------------------

- Collaboration revenue $9.1M, down from $14.9M YoY; net loss $44.5M vs $46.1M in Q3 2022.
- Cash, equivalents & investments $588.9M; management expects sufficient runway through 2025.
- Completed enrollment in pivotal INFRONT-3 Phase 3 trial of latozinemab for FTD-GRN with 103 symptomatic participants.
- Completed enrollment in INVOKE-2 Phase 2 trial of AL002 for early Alzheimer's; data readout expected Q4 2024.
- Reaffirmed FY 2023 guidance: collaboration revenue $90-100M, R&D $210-220M, G&A $60-65M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017023060244/0000950170-23-060244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017023060244/alec-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-060244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer